Cytomel (Liothyronine) Cost in Connecticut 2026

What Does Cytomel (Liothyronine) Actually Cost in Connecticut?

Generic liothyronine averages roughly $35 per month at Connecticut retail pharmacies in 2026, while Pfizer's branded Cytomel carries a list price near $120 per month. The gap between those two numbers is almost entirely insurance and discount-program driven. If you pay cash for the generic, discount cards from GoodRx or the manufacturer can reduce that figure further, sometimes to under $20 for a 30-day supply at chains such as CVS, Walgreens, or Stop & Shop.

Prices vary by dose. A 30-day supply of liothyronine 25 mcg tablets commonly sits in the $20 to $40 range on GoodRx at Connecticut zip codes as of early 2026. The 50 mcg and 75 mcg tablets carry modestly higher prices, though the difference is rarely more than $10 per tier. Brand-name Cytomel costs two to four times more for the same dose because Pfizer's list price does not reflect the aggressive rebating that occurs inside pharmacy benefit managers.

Insurance, when active, typically drops the out-of-pocket cost to a $10 to $30 copay depending on tier placement. Most commercial plans in Connecticut place generic liothyronine on Tier 1 or Tier 2, meaning it is one of the cheaper drugs on most formularies. Patients who want branded Cytomel specifically may face a Tier 3 or non-preferred Tier 4 placement, pushing monthly costs above $60 even with coverage. [1]

GoodRx and similar discount platforms are not insurance. They are negotiated pricing agreements with pharmacy chains. In Connecticut, using a GoodRx coupon at a Rite Aid or Walmart Pharmacy may produce a price below what your insurance copay would be, so it is worth comparing both options before each fill.

Connecticut Medicaid Coverage for Liothyronine

Connecticut Medicaid (HUSKY Health) covers liothyronine for hypothyroidism, but the generic formulation requires prior authorization in most plan pathways. Branded Cytomel almost always requires prior authorization as well, plus a non-preferred brand exception in many managed care organization (MCO) contracts under HUSKY A, B, C, and D.

Prior authorization for liothyronine through Connecticut Medicaid typically asks your prescriber to document why levothyroxine monotherapy is insufficient. The American Thyroid Association's 2014 guidelines state that combination T4/T3 therapy "may be appropriate for a subset of hypothyroid patients," [2] which gives prescribers a recognized clinical basis for the PA request. Approval times at Connecticut MCOs generally run two to five business days when documentation is complete.

Patients on HUSKY Health should ask their prescriber to submit the PA at the same time as the initial prescription. Retroactive PAs are not accepted. Connecticut's Department of Social Services publishes updated preferred drug lists quarterly; checking the current list before your appointment saves time and avoids a denied claim at the pharmacy counter. [3]

Is Compounded Liothyronine Legal in Connecticut?

Compounded liothyronine T3 is legal in Connecticut when prepared by a state-licensed 503A compounding pharmacy. The 503A designation under the Drug Quality and Security Act of 2013 allows a licensed pharmacist to compound a drug for an identified individual patient based on a valid prescription. Connecticut's Department of Consumer Protection, Pharmacy Unit, licenses and inspects these pharmacies. [4]

A 503A compounded T3 product is not FDA-approved and is not bioequivalent-tested against Cytomel. That distinction matters clinically. Bunevicius et al. (NEJM 1999, N=33) showed that replacing 50 mcg of levothyroxine with 12.5 mcg of liothyronine improved mood and neuropsychological performance in hypothyroid patients, but the study used pharmaceutical-grade liothyronine under controlled conditions, not compounded preparations. [5] Clinicians considering compounded T3 should recognize that the evidence base for T3 therapy was built on standardized doses.

Compounded liothyronine in Connecticut costs approximately $40 per month at 503A pharmacies, which is slightly higher than the $35 average for generic Cytomel at retail chains. The price premium reflects the individualized compounding process. Insurance rarely covers compounded T3, and Connecticut Medicaid does not reimburse 503A compounded liothyronine.

503B outsourcing facilities, which operate on a larger scale and supply hospitals and clinics, are federally registered with the FDA. As of 2025, no FDA-registered 503B facility has liothyronine on its active bulk compounding list. [6] This means hospital or clinic-dispensed compounded T3 in Connecticut will come from a 503A pharmacy under a patient-specific prescription.

How Telehealth Prescribing Works for Liothyronine in Connecticut

Connecticut permits telehealth prescribing of liothyronine. The Connecticut Medical Practice Act does not restrict prescription-only medications from being prescribed via synchronous audio-video telehealth, provided the prescriber holds an active Connecticut license or qualifies under the Interstate Medical Licensure Compact (IMLC). [7]

Telehealth visits for thyroid management typically include a review of recent TSH, free T4, and free T3 lab values. Most Connecticut telehealth platforms will not prescribe T3 therapy without recent labs, usually drawn within the past 60 to 90 days. Ordering labs before your first appointment shortens the time to a new prescription by several days.

The prescriber must establish a valid patient-provider relationship before issuing a controlled or prescription-only drug via telehealth. For liothyronine, this generally means a video visit rather than an asynchronous questionnaire. Pharmacies in Connecticut accept electronically transmitted prescriptions for Schedule-exempt drugs like liothyronine without restriction.

Patients using HealthRX's telehealth service in Connecticut receive a follow-up protocol that checks free T3, free T4, and TSH at 6 weeks after any dose change. This interval aligns with the Endocrine Society's clinical practice guidelines, which advise reassessment of thyroid function 6 to 8 weeks after initiating or adjusting T3-containing regimens. [8]

Which Insurance Plans Cover Liothyronine in Connecticut?

Most commercial insurance plans active in Connecticut cover generic liothyronine. The state's largest carriers, including Anthem Blue Cross Blue Shield of Connecticut, Aetna, ConnectiCare, and United Healthcare's individual market plans sold through Access Health CT, all list generic liothyronine on their 2026 formularies. Tier placement differs across plans.

Anthem Connecticut typically places generic liothyronine on Tier 1 with a $0 to $10 copay. Aetna's Choice POS II plans in Connecticut often list it as Tier 2 at $15 to $30. ConnectiCare's EPO plans, which are specific to Connecticut, generally follow a similar Tier 1 or Tier 2 placement. These figures are estimates based on published 2025 to 2026 formulary documents and can shift at annual plan renewal.

Branded Cytomel is non-preferred on most Connecticut commercial formularies. A Tier 3 placement commonly means a $45 to $75 copay, and Tier 4 "non-preferred brand" can mean 40 to 50 percent coinsurance. For most patients, the clinical difference between branded and generic liothyronine does not justify that cost difference, and most Connecticut prescribers default to generic.

Employer-sponsored plans self-funded under ERISA are not subject to Connecticut state insurance mandates. Their formularies are governed by the plan document, not state law. If you are on a self-funded employer plan, confirm liothyronine's tier directly with your pharmacy benefits manager (PBM) rather than relying on the insurance carrier's general formulary. [9]

Connecticut Discount Programs and Manufacturer Savings Cards

Pfizer does not offer a traditional patient assistance program for Cytomel in the same structure as some specialty drugs, but it does operate a savings card program for commercially insured patients that may reduce copays to $0 for up to 12 fills. Patients on government insurance (Medicaid, Medicare, TRICARE) are not eligible for manufacturer savings cards under federal anti-kickback statute guidelines.

For uninsured or underinsured Connecticut residents, the NeedyMeds database lists patient assistance options available in Connecticut for liothyronine, including Pfizer's RxPathways program. [10] Income thresholds and documentation requirements apply.

GoodRx Gold membership, priced at roughly $9.99 per month per household, consistently shows prices below $15 for a 30-day supply of generic liothyronine 25 mcg at Connecticut pharmacies when searched in Hartford, Bridgeport, New Haven, and Stamford zip codes. The discount is applied at the pharmacy counter in place of insurance, not in addition to it.

Connecticut also participates in the 340B drug pricing program, which allows qualifying federally qualified health centers (FQHCs) and safety-net hospitals to purchase outpatient drugs at reduced cost. If you receive primary care at a 340B-covered entity in Connecticut, your liothyronine cost may be substantially lower than retail. Hartford Hospital's outpatient pharmacy, Yale New Haven Health's pharmacy network, and several community health centers in Bridgeport operate under 340B coverage. [11]

Comparing Your Four Main Pricing Pathways in Connecticut

Understanding which of the four main payment pathways applies to your situation takes the guesswork out of the pharmacy counter experience.

Pathway 1: Insurance with generic. If your plan covers generic liothyronine at Tier 1 or Tier 2, your copay will typically be $0 to $30 per month. This is the lowest-cost option for most insured Connecticut residents.

Pathway 2: Cash pay with discount card. GoodRx, RxSaver, or similar platforms reduce the cash price of generic liothyronine to $15 to $35 per month at Connecticut retail pharmacies. No insurance card needed.

Pathway 3: Compounded T3 from a Connecticut 503A pharmacy. Roughly $40 per month, paid out of pocket. Appropriate when a prescriber determines that a non-standard dose or formulation is clinically necessary. Insurance does not cover this pathway.

Pathway 4: Branded Cytomel with manufacturer savings card. If you have commercial insurance and your prescriber specifically requires branded Cytomel, the Pfizer savings card may reduce your monthly cost to near $0 for up to a year of fills. After the savings card period ends, full Tier 3 or Tier 4 cost-sharing resumes.

Patients without insurance who do not qualify for Medicaid should default to Pathway 2. The $35 average cash price for generic liothyronine in Connecticut compares favorably with the national average of approximately $38, according to 2025 GoodRx pricing data across major Connecticut pharmacy chains. [12]

Clinical Background: Why T3 Therapy Is Prescribed Alongside or Instead of T4

Liothyronine is the synthetic form of triiodothyronine (T3), the metabolically active thyroid hormone. Most patients with hypothyroidism do well on levothyroxine (T4) alone because peripheral tissues convert T4 to T3 via deiodinase enzymes. A subset of patients, estimated at 10 to 15 percent in some cohort studies, report persistent symptoms despite normalized TSH on levothyroxine monotherapy. [13]

Bunevicius et al. (NEJM 1999, N=33) found that partial substitution of levothyroxine with liothyronine at a 14:1 ratio (T4 mcg to T3 mcg) improved mood scores and cognitive test performance compared with levothyroxine alone over a 5-week crossover period. The authors concluded, "substitution of liothyronine for a portion of levothyroxine... resulted in better cognitive performance, mood, and quality of life." [5] This trial is frequently cited in clinical rationales for T3 therapy, though its small size and short duration mean larger confirmatory evidence is still accumulating.

The FDA approved liothyronine sodium tablets (NDA 010379) for hypothyroidism, myxedema, and thyroid suppression therapy. The prescribing information specifies starting doses between 25 mcg and 100 mcg daily, titrated based on clinical response and laboratory monitoring. [1] For combination T4/T3 regimens, many endocrinologists start liothyronine at 5 to 12.5 mcg per day to minimize the risk of tachycardia or palpitations that come with rapid T3 absorption.

Half-life matters in dosing decisions. Liothyronine has a serum half-life of roughly 2.5 days compared with levothyroxine's 7-day half-life. This shorter half-life means missed doses produce faster symptom recurrence and that twice-daily dosing is often preferred for patients who are sensitive to peak-trough fluctuations in free T3. [14]

Monitoring Requirements and Lab Costs in Connecticut

Initiating liothyronine therapy in Connecticut requires baseline thyroid labs and follow-up testing. Typical monitoring includes TSH, free T4, and free T3 at baseline, then at 6 weeks after starting or changing dose, then every 3 to 6 months once stable.

Lab costs matter to the total cost-of-treatment calculation. A TSH draw at a Connecticut LabCorp or Quest Diagnostics patient service center runs approximately $35 to $60 cash pay. A free T3 and free T4 panel adds another $40 to $80 cash pay. Insurance covers these tests when ordered for hypothyroidism management. Medicaid covers them under HUSKY Health without additional cost-sharing.

Patients using HealthRX telehealth in Connecticut can use the platform's integrated lab ordering feature to send requisitions directly to LabCorp or Quest locations near them. Hartford, Waterbury, New Haven, Bridgeport, and Stamford all have walk-in patient service centers with next-day results. For patients in rural Litchfield or Windham counties, mobile phlebotomy services are available that collect samples at home.

Cardiovascular monitoring is relevant for any patient over 60 or with known arrhythmia history. Liothyronine's faster absorption rate compared with levothyroxine produces a more pronounced early T3 peak, which may increase heart rate. The American Association of Clinical Endocrinologists (AACE) advises starting with the lowest effective T3 dose and reassessing cardiac symptoms at each follow-up. [15]

Connecticut-Specific Regulatory Notes

Connecticut does not have a state-level thyroid therapy mandate that requires insurers to cover T3 therapy specifically. Coverage decisions for liothyronine follow standard formulary placement rules under Connecticut's insurance statutes administered by the Connecticut Insurance Department.

The Connecticut Pharmacy Act requires any out-of-state pharmacy dispensing to Connecticut residents to hold a Connecticut non-resident pharmacy permit. Patients ordering liothyronine through mail-order pharmacies should confirm the pharmacy holds this permit. CVS Caremark, Express Scripts (Cigna), and OptumRx all hold Connecticut non-resident permits and dispense liothyronine via 90-day mail-order supplies, which typically reduces the per-unit cost by 10 to 15 percent compared with monthly retail fills.

Connecticut's Good Samaritan laws and prescription drug monitoring program (PDMP, known as Connecticut's CURES system) do not currently track liothyronine, as it is not a controlled substance. Prescribers are not required to query the PDMP before prescribing it, which simplifies telehealth workflows compared with states where all prescriptions require PDMP review.